ChromaDex
$9.559876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$9.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$1.83 (-16.04%) Today
-$0.03 (-0.31%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell ChromaDex and other stocks, options, and ETFs commission-free!
About CDXC
ChromaDex Corporation Common Stock, also called ChromaDex, is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA. The listed name for CDXC is ChromaDex Corporation Common Stock.
CEO
Robert N. Fried
Employees
110
Headquarters
Los Angeles, California
Founded
1999
Market Cap
670.76M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
17.20M
High Today
$11.55
Low Today
$9.25
Open Price
$11.54
Volume
3.75M
52 Week High
$23.66
52 Week Low
$2.50
CDXC News
CDXC Earnings
-$0.13
-$0.09
-$0.04
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.09 per share
Actual
Available Mar 10, After Hours